Monopar Therapeutics (MNPR) Share-based Compensation (2017 - 2025)
Monopar Therapeutics (MNPR) reported Share-based Compensation of -$3.4 million for Q4 2025, down 176.24% on a YoY basis from $4.5 million in Q4 2024, and down 140.03% sequentially from $8.6 million in Q3 2025.
Monopar Therapeutics (MNPR) Share-based Compensation (2017 - 2025) Analysis & Trends
Monopar Therapeutics (MNPR) has 9 years of Share-based Compensation data on file, last reported at -$3.4 million in Q4 2025.
- For the quarter ending Q4 2025, Share-based Compensation fell 176.24% year-over-year to -$3.4 million; the trailing twelve-month figure through Dec 2025 stood at $1.4 million (down 72.93% YoY), and the FY2025 full-year result was $16.4 million, up 260.26% from the prior year.
- Share-based Compensation retreated to -$3.4 million in Q4 2025, from $8.6 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $9.8 million in Q1 2025 to a low of -$3.4 million in Q4 2025.
- A 5-year average of $1.5 million and a median of $339412.5 in 2021 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation tumbled 461.87% in 2023 and jumped 5799.99% in 2025, its largest moves.
- Tracing MNPR's Share-based Compensation over 5 years: stood at $350164.0 in 2021, then increased by 12.35% to $393417.0 in 2022, then plunged by 461.87% to -$1.4 million in 2023, then surged by 417.14% to $4.5 million in 2024, then tumbled by 176.24% to -$3.4 million in 2025.
- Business Quant data shows MNPR's Share-based Compensation at -$3.4 million in Q4 2025, $8.6 million in Q3 2025, and $8.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Monopar Therapeutics | 707.36 Mn | 645.53 Mn | - | -3.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.44 Mn |
| Dec 31, 2025 | -3.44 Mn |
| Sep 30, 2025 | 8.60 Mn |
| Sep 30, 2025 | 8.60 Mn |
| Jun 30, 2025 | 8.80 Mn |
| Jun 30, 2025 | 8.80 Mn |
| Mar 31, 2025 | 9.80 Mn |
| Mar 31, 2025 | 9.80 Mn |
| Dec 31, 2024 | 4.51 Mn |
| Dec 31, 2024 | 4.51 Mn |
| Sep 30, 2024 | 145,763.00 |
| Sep 30, 2024 | 145,763.00 |
| Jun 30, 2024 | 181,084.00 |
| Jun 30, 2024 | 181,084.00 |
| Mar 31, 2024 | 328,661.00 |
| Mar 31, 2024 | 328,661.00 |
| Dec 31, 2023 | -1.42 Mn |
| Dec 31, 2023 | -1.42 Mn |
| Sep 30, 2023 | 226,054.00 |
| Sep 30, 2023 | 226,054.00 |